Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus (NASDAQ: MRUS) is a clinical-stage immuno-oncology company specializing in the discovery and development of bispecific antibody therapeutics to treat cancer. Leveraging its proprietary Biclonics® platform, the company designs antibodies that simultaneously engage two distinct targets on cancer cells or immune cells, with the goal of enhancing anti-tumor activity while minimizing off-target effects. Research and development activities span from early candidate selection through preclinical validation and clinical-stage trials, underscoring Merus’s commitment to advancing novel treatments for solid tumors and hematologic malignancies.

The company’s leading pipeline candidate, zenocutuzumab (MCLA-128), targets HER2 and HER3 receptor pathways and is being investigated in multiple solid tumor indications, including breast, lung and pancreatic cancers. Additional clinical programs focus on novel biclonal antibodies directed at immune checkpoints, growth factor receptors and T-cell co-stimulators. Merus also maintains a robust portfolio of preclinical assets designed to address unmet needs in oncology by combining precision-engineered binding domains with optimized pharmacological profiles.

Headquartered in the Netherlands with a significant presence in the United States, Merus conducts global clinical trials in collaboration with academic research centers and pharmaceutical partners. The company’s international footprint includes laboratories and offices in Utrecht and Cambridge, Massachusetts, facilitating seamless coordination between European and North American operations. Strategic alliances have been established to expand development capabilities, accelerate regulatory filings and explore combination regimens with established oncology agents.

Founded in 2008 by a team of antibody engineering specialists, Merus has since built a leadership team of experienced drug developers and industry veterans. The company is led by President and Chief Executive Officer Rob Icke, Ph.D., who brings over two decades of biopharmaceutical leadership, supported by a multidisciplinary executive staff in research, clinical development and regulatory affairs. Through its innovative platform and collaborative approach, Merus aims to deliver next-generation antibody therapies that improve outcomes for patients with cancer worldwide.

Key Stats

• Today's Range: $53.22 to $54.11
• 50-Day Range: $39.30 to $62.42
• 52-Week Range: $33.19 to $62.98
• Volume: 222,443 shs
• Average Volume: 738,077 shs
• Market Capitalization: $3.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $84.64
• Consensus Rating: Buy

Merus Stock Analysis - MarketRank™

Merus scored higher than 38% of companies evaluated by MarketBeat, and ranked 2368th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Merus has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 12 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Merus has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merus is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merus is -13.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Merus has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.57% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Merus has recently increased by 7.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merus does not currently pay a dividend.

Dividend Growth

Merus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.57% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in Merus has recently increased by 7.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.56

News Sentiment

Merus has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Merus this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,793,840.00 in company stock.

Percentage Held by Insiders

Only 4.57% of the stock of Merus is held by insiders.

Percentage Held by Institutions

96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRUS Stock Analysis - Frequently Asked Questions

How have MRUS shares performed this year?

Merus' stock was trading at $42.05 on January 1st, 2025. Since then, MRUS stock has increased by 28.0% and is now trading at $53.84.

How were Merus' earnings last quarter?

Merus N.V. (NASDAQ:MRUS) announced its earnings results on Wednesday, May, 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.23. The biotechnology company had revenue of $26.49 million for the quarter, compared to analysts' expectations of $7.82 million. Merus had a negative trailing twelve-month return on equity of 35.99% and a negative net margin of 506.73%.

When did Merus IPO?

Merus (MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $84.64
• High Stock Price Target: $110.00
• Low Stock Price Target: $67.00
• Potential Upside/Downside: +57.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -506.73%
• Pretax Margin: -490.45%
• Return on Equity: -35.99%
• Return on Assets: -29.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.86
• Quick Ratio: 5.86

Sales & Book Value

• Annual Sales: $36.13 million
• Price / Sales: 103.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 5.69

Miscellaneous

• Outstanding Shares: 69,210,000
• Free Float: 66,051,000
• Market Cap: $3.73 billion
• Optionable: Optionable
• Beta: 1.00